Global Longevity Summit 2025: Spotlight on Dr. Steve Horvath, New Advisory Board Members, and Early Registration Opportunity
GENEVA, SWITZERLAND, June 12, 2025 (GLOBE NEWSWIRE) -- Biogerontologist and epigenetic researcher Dr. Steve Horvath will headline the event as its keynote speaker and will be formally recognized as the recipient of the 2025 Global Longevity Award for his exceptional work in the development of the epigenetic clock - a breakthrough that continues to reshape our understanding of biological aging and predictive biomarkers.
The Global Longevity Summit convenes from October 28–30, 2025, at the Genolier Innovation Hub in Geneva, Switzerland. The event brings together a distinguished cohort of 300 global leaders across healthcare, science, business, and capital. Under this year's theme, 'Mastering the Aging Clock: The Science of Longevity,' the program will feature cutting-edge insight into epigenetics, regenerative medicine, AI-powered health optimization, and precision intervention strategies.
The Summit also expands its leadership circle with new Scientific and Professional Advisory Board members, each selected for their expertise in advancing healthy human lifespan. These new appointments reinforce the event's global vision and commitment to multidisciplinary innovation.
This year's event is shaping up to be the most anticipated yet - and with demand rising, early registration is strongly encouraged. Ticket prices will increase on July 1, and delegate spots are limited. Interested participants are urged to secure access now to avoid missing this landmark opportunity.
The Global Longevity Summit is an invitation-only event requiring participant approval. Qualified professionals and executives in the longevity ecosystem may apply to join at informaconnect.com/global-longevity-summit/.
About the Global Longevity SummitThe Global Longevity Summit is the definitive gathering of international leaders dedicated to advancing human longevity through scientific innovation and strategic collaboration. The invitation-only conference unites experts, entrepreneurs, and investors to accelerate breakthroughs in life extension and power the future of healthy aging.
CONTACT: Drew Wilson Global Longevity Summit (+1) 713-725-8983 drew.wilson@informa.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
a few seconds ago
- Associated Press
Medical Teams International Launches Campaign to Raise $1 Million USD by August 31
Portland, Oregon USA, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Medical Teams International, a global health and humanitarian relief organization, has launched 'Rise to the Moment,' a fundraising campaign to help drive our urgent work to provide compassionate, life-saving healthcare to people in crisis around the world. The goal is to raise $1 million USD by August 31, leveraging a $500K match donation made to the campaign. Severe Funding Crisis The global humanitarian aid sector has faced enormous funding challenges in 2025, due to the U.S. government's dissolution of USAID, deep funding cuts to many UN agencies, and decreased availability of funds worldwide. Despite sharply rising needs due to hunger, conflict, and displacement, the U.S. and the international community are pulling back aid, impacting some of the world's most vulnerable people. Among them are roughly 122 million people around the world who have been forced to flee their homes. Families and individuals who have been displaced experience high levels of physical and emotional distress and are at greater risk of life-threatening illnesses. In Uganda, home to nearly 2 million refugees, stockouts of key medication and supplies due to procurement delays by UNHCR are increasing. Also, high workloads for medical staff – 75 consultations per clinician per day last quarter – mean patients who are fortunate enough to be seen are receiving less time and attention. Medical Teams' Work Medical Teams works in seven countries including the U.S., and our dedicated local staff and community health volunteers provide essential healthcare to refugees, internally displaced people, and host communities. For 45 years, we've been saving lives, alleviating suffering, and restoring human dignity by offering comprehensive services in health, nutrition, and mental health. We serve in complex humanitarian settings where healthcare systems have been disrupted, access to care is limited or nonexistent, and external assistance is required. Available Aid Difficult to Access Many of Medical Teams' health services fit into the current administration's definition of life-saving work and have thus been deemed eligible for humanitarian waivers and reimbursement of program expenses incurred earlier this year. However, many do not qualify but are potentially life-saving. These activities, like addressing mental health conditions such as PTSD, as well as moderate malnutrition, are the pillars that support the safety and well-being of children and families at border points and in refugee camps and settlements. For example, food rations have been scaled back significantly and nutrition supplements for pregnant and lactating women are no longer available in many areas. 'All of our staff and volunteers are determined to rise to the moment to meet more needs and save more lives, and we're so thankful for the donors who have already joined us,' said Eric Ha, Medical Teams President & CEO. 'However, as we navigate this time of great uncertainty, we need many more people of goodwill to join us. We believe in the American people's compassion, generosity, and sense of common humanity. If there was ever a time to demonstrate those virtues, it's now.' $500K Campaign Match Medical Teams is grateful that an anonymous donor has committed a $500,000 match to the Rise to the Moment campaign. We aim to raise another $500,000 by August 31 to maximize the donation, enabling us to provide vital health services to people in crisis and facing vulnerability. For more information or to give, visit and About Medical Teams International Founded in 1979, Medical Teams International provides life-saving medical care for people in crisis, such as refugees, internally displaced persons, and survivors of conflict zones and natural disasters. Daring to love like Jesus, we care for the whole person and serve all people. Learn more at and on social media using @medicalteams. Attachments Karen Piatt Medical Teams International 2067080355 [email protected]
Business Upturn
2 days ago
- Business Upturn
Folqs Highlights First-Day, Grass-Fed Colostrum Powder Amid Global Surge in Demand
Wilmington, DE, Aug. 08, 2025 (GLOBE NEWSWIRE) — Folqs, a U.S.-based wellness company, introduces new consumer product, Folqs First-Day Colostrum Powder . This positions the company within the growing colostrum supplement sector, which has recently exceeded $3 billion in global market value, according to industry research. The product is formulated from bovine colostrum collected on the first day after birth and sourced exclusively from grass-fed, pasture-raised cows located in the United States. Processing and packaging are conducted domestically at an FDA-registered facility that operates under Current Good Manufacturing Practices (cGMP). This announcement marks Folqs' formal entry into a sector experiencing measurable growth. A 2025 report from Grand View Research estimates the global colostrum market will sustain a compound annual growth rate of approximately 7% through 2030. Concurrently, online search interest in colostrum-related supplements has risen 68% year-over-year, based on recent data from Google Trends. Product Developed for Adults Focused on Dietary Supplementation According to the company, Folqs First-Day Colostrum Powder is unflavoured and designed to dissolve quickly into liquids. It is intended for use by adults who are exploring food-based supplement options. The product contains naturally occurring bioactive compounds found in colostrum, including immunoglobulins and growth factors Folqs has indicated it does not add any artificial ingredients or flavoring agents during production. The colostrum used is collected only after the needs of the newborn calf have been met, under a sourcing policy the company refers to as 'Calf-First.' This policy stipulates that calves receive their full share before any surplus is gathered for human use. Each batch undergoes third-party testing, with screening for microbiological content, heavy metals, and nutritional composition. Documentation of testing is maintained for internal quality control and regulatory compliance. Market Timing Reflects Broader Consumer Shift Toward Food-Based Supplements The decision to launch into the colostrum segment comes at a time when consumer attention to supplement sourcing and transparency has intensified. Data from the Council for Responsible Nutrition (2024) indicates that only 52% of U.S. supplement users consider product labels to be 'very trustworthy.' Folqs' leadership said that these statistics informed its approach to formulation, production, and consumer messaging. 'Consumers are tired of vague 'proprietary blends.' By sharing our lab reports and guaranteeing results, we're setting a new transparency bar for the $3 billion colostrum space,' said David Johnson, Company Spokesperson. Johnson noted that Folqs will prioritize third-party testing as part of its operational model. 'We've aligned our product development process with the demand for greater transparency in supplement sourcing,' Johnson said. 'Every decision, from raw ingredient origin to packaging, was shaped by current expectations in the space.' Availability and Purchasing Details Folqs First-Day Colostrum Powder is exclusively available through the company's official website, Pricing, serving guidelines, and detailed product specifications are provided on the site. No retail or third-party distribution agreements were announced at the time of release. The product is offered under a customer refund policy referred to as the 90-Day Money-Back guarantee, allowing purchasers to request a refund if unsatisfied. Folqs stated that this policy was introduced to address consumer hesitations common in the dietary supplement category. No Comparisons or Claims Made Against Competing Brands Under established content distribution standards, Folqs has not made any comparative statements regarding other colostrum products on the market. Folqs emphasized that its entry into the colostrum market is grounded in sourcing and production controls, rather than marketing-driven distinctions. It has not used or referenced any competing companies or their product names in its communications. Regulatory and Testing Framework The colostrum is processed in a facility that meets federal registration and cGMP compliance criteria. Third-party laboratories are used to conduct batch testing. All production occurs within the United States, and the company maintains that its supply chain remains fully domestic at this time. No claims have been made about the product's ability to prevent, treat, or cure any medical condition. The company has not submitted its product for review by the Food and Drug Administration, as it is sold as a dietary supplement and not a drug. About Folqs Folqs is a privately held wellness company headquartered in Wilmington, Delaware. It specializes in sourcing and manufacturing food-based supplements. The company's operational focus includes domestic production, third-party testing, and ingredient transparency. Folqs First-Day Colostrum Powder is its first product offering. Media Contact Company Name: FolqsContact Person: David Johnson Email: [email protected] Phone: 800-975-4495Country: United States Website:
Business Upturn
2 days ago
- Business Upturn
Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System
FRANKFURT, Germany, Aug. 08, 2025 (GLOBE NEWSWIRE) — In response to recent outbreaks of Chikungunya fever, Anbio Biotechnology has announced the launch of its Chikungunya IgM/IgG Rapid Test, offering clinicians and public health authorities a fast, accessible diagnostic tool at the point of care. As cases continue to rise across tropical and subtropical regions, timely detection and differentiation from other arboviral infections like Dengue and Zika remain critical. The test, based on immunochromatographic technology, enables reliable qualitative detection of Chikungunya-specific antibodies in human serum, plasma, or whole blood. This addition strengthens Anbio's infectious disease diagnostics portfolio and supports public health efforts in responding to emerging outbreaks. In parallel, Anbio is advancing the boundaries of decentralized molecular diagnostics with the launch of its new AP-100 Ultra-Fast PCR system, designed to bring laboratory-grade testing capabilities directly to the point of care. 'Outbreaks demand speed. The AP-100 collapses hours of traditional PCR into minutes, without compromising accuracy,' said Michael Lau, CEO of Anbio Biotechnology. The AP-100 utilizes an advanced microfluidic thermal cycling system combined with high-efficiency enzymatic amplification chemistry, enabling direct processing of swab samples without the need for nucleic acid extraction. Its integrated design streamlines sample-to-result workflows, making it well-suited for deployment in both centralized laboratories and decentralized, point-of-care environments. Key highlights: 15-minute PCR results from raw sample to answer Extraction-free workflow with no hazardous reagents Compact 668g device for mobile or near-patient testing Broad pathogen coverage, including COVID-19, Flu A/B, RSV, MP, and ADV Lab-comparable accuracy validated against mainstream PCR platforms While initially focused on respiratory infections, the AP-100 is designed as a flexible molecular platform. In line with its global infectious disease strategy, Anbio is expanding the assay portfolio to include tests for tuberculosis (TB) and human papillomavirus (HPV), extending its role from rapid outbreak response to sustained disease management. 'Whether it's vector-borne fevers or respiratory pandemics, we believe diagnostics should move as fast as the threat,' Lau added. With its combination of speed, mobility, and lab-grade precision, Anbio's new-generation POCT PCR system strengthens healthcare capacity in both well-resourced and resource-limited settings, advancing global preparedness for infectious disease threats. About Anbio Biotechnology Anbio Biotechnology is a globally oriented in vitro diagnostics (IVD) company providing a broad range of solutions, including immunofluorescence, dry chemistry, chemiluminescence, molecular diagnostics, rapid testing and veterinary diagnostics. With operations across multiple regions, the company works to enhance the availability of reliable and timely diagnostics, supporting better decision-making in healthcare settings worldwide. For more information about Anbio Biotechnology, follow us for the latest news and updates. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
